Skip to main content
. Author manuscript; available in PMC: 2022 Feb 15.
Published in final edited form as: Clin Cancer Res. 2020 Oct 12;27(4):992–1002. doi: 10.1158/1078-0432.CCR-20-1690

Figure 1.

Figure 1.

A. Confirmed best response based on tumor burden. Investigator-assessed best percentage change in tumor size from baseline is shown for each patient whose disease was assessable by RECIST 1.1 criteria. Patients (x-axis) are color-coded according to best overall response. B. Tumor response over time in treated patients. Tumor response over duration on treatment (A) and percent change in tumor size from baseline over analysis time (B) are shown for each patient, color-coded by best overall response. C. Confirmed Best Overall Systemic Response. CI, confidence interval; CNS, central nervous system; CR, complete response; N, number of patients in population; n, number of patients in specified category; NE, non-evaluable; PD, progressive disease; PR, partial response; SD, stable disease. Response criteria were from RECIST 1.1 and were investigator-assessed. Confidence intervals are based on the Clopper-Pearson method. aOne patient did not have post baseline tumor assessment.